Search

Objective: The aim of this study is to evaluate the prognostic value of the modified Glasgow prognostic score (mGPS) in advanced esophageal squamous cell carcinoma (SCC) patients. Methods: The study enrolled 311 patients with advanced esophageal SCC from January 2012 to December 2018. Univariate and multivariate analyses were calculated by the Cox proportional hazards regression model in advanced esophageal SCC patients. The Kaplan–Meier method was used to evaluate the ability of the mGPS for survival rates. Propensity score‐matched (PSM) analysis was carried out to balance imbalanced variables. Results: The Cox proportional hazards analysis showed that factors including M stage, ECOG, mGPS group, and sex were identified as independent predictors. The mGPS presented a good level of overall survival (OS) prediction with a risk‐adopted classification for advanced esophageal SCC patients. The survival rates in advanced esophageal SCC patients with mGPS 0, 1, and 2 were 18.8%, 8.4%, and 4.2%, respectively (p < 0.001). Moreover, before and after PSM, the mGPS was associated with 3‐year survival rates of advanced esophageal SCC patients in the Kaplan–Meier survival analysis. In addition, the mGPS for OS prediction demonstrated better performance than sex and ECOG score. The area under curve (AUC) of the mGPS combined with M stage for the prognosis of advanced esophageal SCC was 0.677 (0.592–0.763). Conclusion: The mGPS is a cost‐effective, accessible tool capable of prognosticating in this cohort. It could be a useful surveillance system of prognosis in advanced esophageal SCC patients. [ABSTRACT FROM AUTHOR]

Metaplastic breast cancer (MBC) is a rare and aggressive form of breast cancer. The effectiveness of chemotherapy (CT) for MBC remains controversial. The present study aimed to evaluate the efficacy of CT combined hormone receptor (HR) status on MBC patients with high risk (T1-4N2-3M0 and T4N0-1M0) by propensity-score matching (PSM). A retrospective study was performed to analyze MBC from the SEER database. Breast cancer-specific survival (BCSS) was analyzed using the Kaplan–Meier curve. Cox proportional hazard models were used to assess BCSS. PSM was used to make 1:1 case-control matching. This study identified 3116 patients. The median follow-up time was 44 months (range, 1–321 months). About 62.5 % of patients received CT. 23.0 % of patients were HR-positive. Recurrence risk had a significant difference between the HR-negative and HR-positive groups. In the multivariable Cox regression model, CT had no benefit for MBC patients. HR status was not associated with a better prognosis. In subgroup analysis, the Kaplan–Meier analysis showed that HR-negative MBC with intermediate-risk benefited from CT. For HR-positive MBC, patients with intermediate and high risk also benefited from CT. After PSM, neither CT nor HR status was not related to better BCSS. Moreover, the use of CT could only improve the survival of HR-positive MBC patients with high risk. PSM analysis showed that HR status was not associated with a better prognosis. CT was not a significant prognostic factor for prognosis. However, HR-positive MBC patients with high risk might benefit from CT. • Metaplastic breast cancer (MBC) is a rare and aggressive form of breast cancer. • Hormone receptor (HR) status was not associated with a better prognosis. • Chemotherapy (CT) was not a significant prognostic factor for prognosis. • HR-positive MBC patients with high risk might benefit from CT. [ABSTRACT FROM AUTHOR]

• PTV dose coverage has a significant impact on locoregional recurrence in NPC clinical routine patients. • D90 is the most important dose–volume factor for NPC locoregional recurrence. • The effect of clinical factors on patient's outcome was filtered out by propensity score matching. To analyze the impact of target dosimetry using propensity score matching (PSM) on patients' locoregional recurrence for nasopharyngeal carcinoma (NPC) and to find significant dose–volume factors of recurrence. Sixty-eight nasopharyngeal carcinoma (NPC) patients with recorded locoregional recurrence were enrolled in this study. These patients were treated with IMRT in 2009–2010 in our department. Another 198 NPC patients without recurrence were randomly selected from the same treatment time period. The median follow-up time for all patients was 49.0 months. PSM was performed to match the recurrence and nonrecurrence cohorts. Dose–volume histograms (DVHs) of treatment planning were extracted for statistical analysis. Cox hazard model and Kaplan-Meier log-rank analysis were performed to evaluate correlations between PTV dose coverage and local/region recurrence. Propensity score matching balanced the clinical factors in two matches. Univariate cox survival model showed D90 and D95 were significantly correlated to the recurrence, and the D90 was the most significant (p = 0.036) one. The results of multivariate analysis show that only D90 is required for recurrence prediction when collinear dosimetric factors are considered. KM log-rank analysis showed that patients have significant local/regional control differences (p -value = 0.036, log-rank) in the D90 >101% and D90 <101% groups. D90 corresponds to significant dose–volume factors. PTV dose coverage has a significant impact on locoregional recurrence in NPC clinical routine patients. [ABSTRACT FROM AUTHOR]

Purpose: We conducted this large population-based study to investigate the prognostic significance of N1c. Methods: Patients diagnosed with colorectal cancer from the surveillance, epidemiology, and end results (SEER) database between January 1, 2010, and December 31, 2010, were included in the sample. The primary outcome of interest used in our study was cause-specific survival (CSS). Cox proportional hazards models and Kaplan–Meier methods were used to evaluate the prognostic value of N1c. Propensity score matching (PSM) was implemented to reduce the possibility of selection bias using a logistic regression model. Results: A total of 19,991 patients diagnosed with colorectal cancer were identified from the SEER database. The median follow-up time of the whole cohort was 60 months (0–71 months). Multivariate Cox analysis showed that N1c was associated with significantly higher risk of colorectal cancer-specific mortality compared with N0 (HR = 1.962, 95%CI = 1.642 to 2.343, P < 0.001) and N1a (HR = 0.818, 95%CI = 0.678 to 0.987, P = 0.036); N1c was associated with significantly lower risk of colorectal cancer-specific mortality compared with N2a (HR = 1.296, 95%CI = 1.081 to 1.554, P = 0.005) and N2b (HR = 1.663, 95%CI = 1.391 to 1.989, P < 0.001). Yet the CSS difference between N1b and N1c did not achieve statistical difference (HR = 1.089, 95%CI = 0.909 to 1.304, P = 0.354). Conclusions: The large population-based and propensity score-matched study with long follow-up time provides the first evidence that CSS difference between N1b and N1c does not achieve a statistical difference. [ABSTRACT FROM AUTHOR]

Purpose: This study aimed to investigate the implications of preoperative serum carcinoembryonic antigen (CEA) elevation in cause-specific survival (CSS) of patients diagnosed with stage I (T1N0M0 and T2N0M0) colon cancer. Methods: Eligible patients diagnosed with stage I colon cancer from the Surveillance, Epidemiology, and End Results (SEER) database from January 2004 to December 2010 were included in this respective and propensity score–matched (PSM) study. Some Cox proportional hazards models were constructed to identify prognostic factors associated with oncologic outcomes of colon cancer. Pearson's chi-squared tests and Kaplan–Meier methods were performed. Results: The median follow-up time of the whole cohort was 79 months. A total of 16,659 patients diagnosed with stage I colon cancer were identified from the SEER database. Multivariate Cox analyses showed that stage T1N0M0 in the context of serum CEA elevation (T1, CEA+) presented up to 158.4% increased risk of colon cancer-specific mortality compared with stage T1N0M0 in the context of normal serum CEA [hazard ratio (HR) = 2.584, 95% confidence interval (CI) = 2.167–3.082, P < 0.001]. After PSM, Kaplan–Meier survival curves of stage T1N0M0 colon cancer showed that 5-year CSS rates of normal and elevated CEA were 94.8% and 96.6% (P < 0.001). Conclusions: This large population-based and propensity score–matched study with long follow-up time provides the first evidence that stage T1N0M0 colon cancer with the elevation of preoperative serum CEA would be a surrogate of aggressive tumor biology and predict poor prognosis. In addition, this subgroup of colon cancer might need to be paid more attention of clinicians. [ABSTRACT FROM AUTHOR]